Teva intros generic Epiduo in the U.S.
JERUSALEM — Teva today announced the launch of its generic Epiduo (adapalene and benzoyl peroxide) gel, 0.1%-2.5%, in the United States. The topical treatment is for patients nine years and older with acne vulgaris.
“I am very pleased that Teva is introducing another first generic product, bringing value to our patients and savings to the U.S. healthcare system,” said Andy Boyer, president and CEO, Global Generic Medicines, North America.
As the first company to file a generic application for Epiduo, Teva said it expects to benefit from 180 days of generic product exclusivity. This launch marks the most recent addition to Teva’s portfolio of more than 40 dermatology products. Adapalene and benzoyl peroxide gel 0.1%-2.5% had annual sales of approximately $251 million in the United States, according to IMS data as of March 2017.